Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012
- 20 February 2008
- journal article
- pediatric oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (6) , 919-924
- https://doi.org/10.1200/jco.2007.14.1812
Abstract
Purpose A phase I trial of the antiangiogenesis agent cilengitide (EMD 121974), an alpha v beta 3,5 integrin antagonist, was performed to estimate the maximum-tolerated dose (MTD) and describe dose...Keywords
This publication has 20 references indexed in Scilit:
- Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant GliomaJournal of Clinical Oncology, 2007
- Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1Neuro-Oncology, 2007
- Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumoursEuropean Journal Of Cancer, 2003
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp LigandScience, 2002
- αv‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascinInternational Journal of Cancer, 2002
- Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an αv Integrin AntagonistNeurosurgery, 2001
- N-Methylated Cyclic RGD Peptides as Highly Active and Selective αVβ3Integrin AntagonistsJournal of Medicinal Chemistry, 1999
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vesselsCell, 1994